Comparing the current results to its competitors, Biomea Fusion Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 24.49 %, recorded in the same quarter.
Biomea Fusion Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 29.62 %
Biomea Fusion Inc 's Comment on Competition and Industry Peers
The company faces competition from major pharmaceutical and specialty pharmaceutical firms, biotechnology companies, academic research institutions, governmental agencies, and public and private research organizations worldwide. Competitors often possess greater financial resources and expertise in research and development, manufacturing, preclinical testing, clinical trials, regulatory approvals, and marketing. Smaller or early-stage companies may also be competitors, particularly through collaborations with larger entities. Competitors may develop products with similar or different mechanisms of action that could be competitive or superior. Competition extends to recruiting qualified personnel, establishing clinical trial sites, patient enrollment, and acquiring complementary technologies. The company is currently the only entity in the United States clinically developing irreversible covalent binders specifically targeting menin, though competitors may develop therapies involving irreversible covalent binding against other protein targets.
June 6, 2024
Biomea Fusion s BMF-219 in Diabetes Placed on Clinical HoldIn a recent press release, Biomea Fusion, Inc. announced that the U.S. Food and Drug Administration (FDA) has placed a full clinical hold on the Phase I/II clinical trials of their investigational covalent menin inhibitor, BMF-219, in type 2 and type 1 diabetes. The ongoing trials, referred to as COVALENT-111 and COVALENT-112 respectively, have been halted until further notice. However, the company will continue to collect safety and efficacy data during this period.The clinical hold comes as a surprise to Biomea Fusion and its investors, as BMF-219 had shown significant promise in earlier studies. Covalent inhibitors like BMF-219 function by binding...
May 30, 2024
Biomea Fusion, a biopharmaceutical company focused on developing innovative therapeutics, recently announced the successful completion of enrollment in the first three arms of the Phase 2 expansion cohorts for their investigational drug, BMF-219. This novel covalent menin inhibitor holds potential in regenerating insulin-producing beta cells, providing a significant breakthrough in the treatment of Type 2 Diabetes.Biomea Fusion s BMF-219:BMF-219 is an investigative compound that works as a covalent menin inhibitor. The primary aim of this drug is to stimulate the regeneration of insulin-producing beta cells, which are critical for glucose metabolism regulation in individuals with Type 2 Diabetes. By targetin...
April 1, 2024
Revolutionary Breakthrough in Diabetes Treatment: Biomea Fusion s BMF-219 Shows Promising Results in Regenerating Insulin-Producing Beta CellsIn a groundbreaking development for the field of diabetes research, Biomea Fusion, a biopharmaceutical company focused on developing innovative therapies, has recently shared initial data from the first two Type 1 diabetes patients dosed with BMF-219. This investigational novel covalent menin inhibitor holds immense potential in regenerating insulin-producing beta cells, offering a ray of hope to millions of people worldwide suffering from diabetes.The Global Diabetes CrisisDiabetes, particularly Type 1 diabetes, is a chronic medical condition that affects millions of ...
January 8, 2024
Combining the forces of cutting-edge research and medical innovation, Biomea Fusion has recently announced a significant milestone in their Phase II clinical trial, COVALENT-112. The study marks the dosing of the first patient with Type 1 Diabetes, using their novel investigational drug, BMF-219. This groundbreaking covalent menin inhibitor holds immense promise in regenerating insulin-producing beta cells, offering hope for a potential cure for diabetes.Type 1 Diabetes, also known as juvenile diabetes, is a chronic autoimmune condition that affects millions of individuals worldwide. It occurs when the immune system mistakenly attacks and destroys insulin-producing beta cells in the pancreas. As a result, pa...
Nurix Therapeutics Inc's business model involves developing targeted protein degradation therapies to treat diseases by modulating the body's cellular protein levels.
NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.
Sources:
Biomea Fusion Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Biomea Fusion Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
